Abstract
Neurodegenerative disorders, e.g. Parkinson’s, Huntington’s and Alzheimer’s diseases are distinct clinical and pathological entities sharing a number of leading features in their underlying processes. These common features involve the disturbances in the normal functioning of the mitochondria and the alterations in the delicate balance of tryptophan metabolism. The development of agents capable of halting the progression of these diseases is in the limelight of neuroscience research. This review highlights the role of mitochondria in the development of neurodegenerative processes with special focus on the involvement of neuroactive kynurenines both as pathological agents and potential targets and tools for future therapeutic approaches by providing a comprehensive summary of the main streams of rational drug design and giving an insight into present clinical achievements.
Keywords: Clinical trials, drug discovery, excitotoxicity, kynurenic acid, kynurenine system, mitochondria, neurodegeneration, neuroprotection, quinolic acid, tryptophan metabolism
Current Medicinal Chemistry
Title:Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Volume: 19 Issue: 13
Author(s): L. Szalardy, P. Klivenyi, D. Zadori, F. Fulop, J. Toldi and L. Vecsei
Affiliation:
Keywords: Clinical trials, drug discovery, excitotoxicity, kynurenic acid, kynurenine system, mitochondria, neurodegeneration, neuroprotection, quinolic acid, tryptophan metabolism
Abstract: Neurodegenerative disorders, e.g. Parkinson’s, Huntington’s and Alzheimer’s diseases are distinct clinical and pathological entities sharing a number of leading features in their underlying processes. These common features involve the disturbances in the normal functioning of the mitochondria and the alterations in the delicate balance of tryptophan metabolism. The development of agents capable of halting the progression of these diseases is in the limelight of neuroscience research. This review highlights the role of mitochondria in the development of neurodegenerative processes with special focus on the involvement of neuroactive kynurenines both as pathological agents and potential targets and tools for future therapeutic approaches by providing a comprehensive summary of the main streams of rational drug design and giving an insight into present clinical achievements.
Export Options
About this article
Cite this article as:
Szalardy L., Klivenyi P., Zadori D., Fulop F., Toldi J. and Vecsei L., Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects, Current Medicinal Chemistry 2012; 19 (13) . https://dx.doi.org/10.2174/092986712800167365
DOI https://dx.doi.org/10.2174/092986712800167365 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology Maternal Exposure to Quetiapine: Effects on Structural Changes in Developing Brain and its Lasting Impact on Neurobehavioral Impairments in Rat Offspring
Current Psychopharmacology Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations
Recent Patents on Biomedical Engineering (Discontinued) Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets Parasite Prolyl Oligopeptidases and the Challenge of Designing Chemotherapeuticals for Chagas Disease, Leishmaniasis and African Trypanosomiasis
Current Medicinal Chemistry The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Current Medicinal Chemistry Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Equibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia
Current Drug Therapy Effects of Maternal Obesity on Maternal and Fetal Health
Current Women`s Health Reviews Bioactive Compounds Hold Up- Bacillus amyloliquefaciens as a Potent Bio-Control Agent
The Natural Products Journal Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery